ProPublica

Journalism in the Public Interest

Cancel

Prescriber Checkup

Prescriber Checkup » Hawaii » Hematology Oncology

Top Hematology Oncology Prescribers in Hawaii

Top Prescribers

Providers are grouped by the primary specialty they listed when applying for a national health ID number. This doesn’t necessarily mean the person has special training or certification. Specialty is self-reported by providers and may have changed. Patients and claims shown are for Medicare Part D only.

Prescriber Claims Filled Total Cost Medicare Part D Patients Claims for Brand Name Drugs Schedule Two Schedule Three Dangerous Drugs to Seniors Brand Name Drugs Prescription Price
TAYING YANG MD

Hematology Oncology

8,406

$507K

331
257 are 65+

15%
patients receiving schedule two controlled substances

Avg: 11%

19%
patients receiving schedule three controlled substances

Avg: 8%

4%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 2%

20%
prescriptions for brand name drugs

Avg: 20%

$60
Average prescription price

Avg: $396

JONATHAN CHO M.D.

Hematology Oncology

2,153

$1.15M

318
271 are 65+

9%
patients receiving schedule two controlled substances

Avg: 11%

5%
patients receiving schedule three controlled substances

Avg: 8%

0%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 2%

21%
prescriptions for brand name drugs

Avg: 20%

$534
Average prescription price

Avg: $396

IAN OKAZAKI M.D.

Hematology Oncology

1,572

$894K

232
194 are 65+

15%
patients receiving schedule two controlled substances

Avg: 11%

13%
patients receiving schedule three controlled substances

Avg: 8%

2%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 2%

20%
prescriptions for brand name drugs

Avg: 20%

$569
Average prescription price

Avg: $396

KENNETH SUMIDA M.D.

Hematology Oncology

1,501

$761K

208
195 are 65+

8%
patients receiving schedule two controlled substances

Avg: 11%

7%
patients receiving schedule three controlled substances

Avg: 8%

4%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 2%

17%
prescriptions for brand name drugs

Avg: 20%

$507
Average prescription price

Avg: $396

KAYE KAWAHARA M.D.

Hematology Oncology

1,272

$768K

193
181 are 65+

8%
patients receiving schedule two controlled substances

Avg: 11%

0%
patients receiving schedule three controlled substances

Avg: 8%

2%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 2%

19%
prescriptions for brand name drugs

Avg: 20%

$604
Average prescription price

Avg: $396

MICHELLE MIYASHIRO M.D.

Hematology Oncology

1,234

$394K

157
132 are 65+

10%
patients receiving schedule two controlled substances

Avg: 11%

10%
patients receiving schedule three controlled substances

Avg: 8%

1%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 2%

21%
prescriptions for brand name drugs

Avg: 20%

$319
Average prescription price

Avg: $396

ANTHONY LIM M.D.

Hematology Oncology

1,165

$435K

228
191 are 65+

13%
patients receiving schedule two controlled substances

Avg: 11%

6%
patients receiving schedule three controlled substances

Avg: 8%

2%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 2%

13%
prescriptions for brand name drugs

Avg: 20%

$373
Average prescription price

Avg: $396

MELVIN PALALAY M.D.

Hematology Oncology

1,160

$814K

206
176 are 65+

12%
patients receiving schedule two controlled substances

Avg: 11%

11%
patients receiving schedule three controlled substances

Avg: 8%

2%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 2%

29%
prescriptions for brand name drugs

Avg: 20%

$702
Average prescription price

Avg: $396

C CHOY M.D.

Hematology Oncology

959

$593K

181
154 are 65+

16%
patients receiving schedule two controlled substances

Avg: 11%

11%
patients receiving schedule three controlled substances

Avg: 8%

5%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 2%

16%
prescriptions for brand name drugs

Avg: 20%

$619
Average prescription price

Avg: $396

ARNOLD YEE M.D.

Hematology Oncology

924

$451K

141
107 are 65+

19%
patients receiving schedule two controlled substances

Avg: 11%

9%
patients receiving schedule three controlled substances

Avg: 8%

0%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 2%

22%
prescriptions for brand name drugs

Avg: 20%

$488
Average prescription price

Avg: $396

JARED ACOBA M.D.

Hematology Oncology

915

$783K

146
122 are 65+

16%
patients receiving schedule two controlled substances

Avg: 11%

10%
patients receiving schedule three controlled substances

Avg: 8%

0%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 2%

17%
prescriptions for brand name drugs

Avg: 20%

$856
Average prescription price

Avg: $396

CARL HIGUCHI M.D.

Hematology Oncology

881

$573K

120
116 are 65+

15%
patients receiving schedule two controlled substances

Avg: 11%

20%
patients receiving schedule three controlled substances

Avg: 8%

2%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 2%

21%
prescriptions for brand name drugs

Avg: 20%

$651
Average prescription price

Avg: $396

GORDON NAKANO M.D.

Hematology Oncology

847

$247K

135
122 are 65+

0%
patients receiving schedule two controlled substances

Avg: 11%

0%
patients receiving schedule three controlled substances

Avg: 8%

3%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 2%

16%
prescriptions for brand name drugs

Avg: 20%

$292
Average prescription price

Avg: $396

HUY NGUYEN MD

Hematology Oncology

843

$800K

168
154 are 65+

19%
patients receiving schedule two controlled substances

Avg: 11%

8%
patients receiving schedule three controlled substances

Avg: 8%

0%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 2%

30%
prescriptions for brand name drugs

Avg: 20%

$949
Average prescription price

Avg: $396

REGINALD HO M.D.

Hematology Oncology

679

$44.4K

76
75 are 65+

0%
patients receiving schedule two controlled substances

Avg: 11%

0%
patients receiving schedule three controlled substances

Avg: 8%

0%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 2%

21%
prescriptions for brand name drugs

Avg: 20%

$65
Average prescription price

Avg: $396

ANTHONY DESALVO M.D.

Hematology Oncology

673

$412K

112
91 are 65+

13%
patients receiving schedule two controlled substances

Avg: 11%

10%
patients receiving schedule three controlled substances

Avg: 8%

0%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 2%

25%
prescriptions for brand name drugs

Avg: 20%

$612
Average prescription price

Avg: $396

JENNIFER CARNEY M.D.

Hematology Oncology

641

$341K

160
146 are 65+

9%
patients receiving schedule two controlled substances

Avg: 11%

0%
patients receiving schedule three controlled substances

Avg: 8%

0%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 2%

17%
prescriptions for brand name drugs

Avg: 20%

$532
Average prescription price

Avg: $396

DIPAK GHELANI DO

Hematology Oncology

635

$503K

135
123 are 65+

21%
patients receiving schedule two controlled substances

Avg: 11%

8%
patients receiving schedule three controlled substances

Avg: 8%

2%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 2%

24%
prescriptions for brand name drugs

Avg: 20%

$793
Average prescription price

Avg: $396

MING HE M.D.

Hematology Oncology

184

$68.2K

52
46 are 65+

0%
patients receiving schedule two controlled substances

Avg: 11%

0%
patients receiving schedule three controlled substances

Avg: 8%

0%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 2%

11%
prescriptions for brand name drugs

Avg: 20%

$370
Average prescription price

Avg: $396

Sources

Centers for Medicare and Medicaid Services; National Technical Information Service; First Databank